BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8663205)

  • 1. Isolation of a Chinese hamster ovary cell clone possessing decreased mu-calpain content and a reduced proliferative growth rate.
    Mellgren RL; Lu Q; Zhang W; Lakkis M; Shaw E; Mericle MT
    J Biol Chem; 1996 Jun; 271(26):15568-74. PubMed ID: 8663205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of growth of human TE2 and C-33A cells by the cell-permeant calpain inhibitor benzyloxycarbonyl-Leu-Leu-Tyr diazomethyl ketone.
    Mellgren RL; Shaw E; Mericle MT
    Exp Cell Res; 1994 Nov; 215(1):164-71. PubMed ID: 7957664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the growth of WI-38 fibroblasts by benzyloxycarbonyl-Leu-Leu-Tyr diazomethyl ketone: evidence that cleavage of p53 by a calpain-like protease is necessary for G1 to S-phase transition.
    Zhang W; Lu Q; Xie ZJ; Mellgren RL
    Oncogene; 1997 Jan; 14(3):255-63. PubMed ID: 9018111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The design of peptidyldiazomethane inhibitors to distinguish between the cysteine proteinases calpain II, cathepsin L and cathepsin B.
    Crawford C; Mason RW; Wikstrom P; Shaw E
    Biochem J; 1988 Aug; 253(3):751-8. PubMed ID: 2845932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specificities of cell permeant peptidyl inhibitors for the proteinase activities of mu-calpain and the 20 S proteasome.
    Mellgren RL
    J Biol Chem; 1997 Nov; 272(47):29899-903. PubMed ID: 9368065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The affinity-labelling of cathepsin S with peptidyl diazomethyl ketones. Comparison with the inhibition of cathepsin L and calpain.
    Shaw E; Mohanty S; Colic A; Stoka V; Turk V
    FEBS Lett; 1993 Nov; 334(3):340-2. PubMed ID: 8243643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biotin-labelled peptidyl diazomethane inhibitors derived from the substrate-like sequence of cystatin: targeting of the active site of cruzipain, the major cysteine proteinase of Trypanosoma cruzi.
    Lalmanach G; Mayer R; Serveau C; Scharfstein J; Gauthier F
    Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):395-9. PubMed ID: 8809025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined effect of epinephrine and exercise on calpain/calpastatin and cathepsin B and L activity in porcine longissimus muscle.
    Ertbjerg P; Henckel P; Karlsson A; Larsen LM; Møller AJ
    J Anim Sci; 1999 Sep; 77(9):2428-36. PubMed ID: 10492449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cathepsin B and L activities in isolated osteoclasts.
    Rifkin BR; Vernillo AT; Kleckner AP; Auszmann JM; Rosenberg LR; Zimmerman M
    Biochem Biophys Res Commun; 1991 Aug; 179(1):63-9. PubMed ID: 1883385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for participation of a calpain-like cysteine protease in cell cycle progression through late G1 phase.
    Mellgren RL
    Biochem Biophys Res Commun; 1997 Jul; 236(3):555-8. PubMed ID: 9245687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo effect of a beta-adrenergic agonist on activity of calcium-dependent proteinases, their specific inhibitor, and cathepsins B and H in skeletal muscle.
    Kretchmar DH; Hathaway MR; Epley RJ; Dayton WR
    Arch Biochem Biophys; 1989 Nov; 275(1):228-35. PubMed ID: 2573315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysosomal cysteine endopeptidases mediate interleukin 1-stimulated cartilage proteoglycan degradation.
    Buttle DJ; Saklatvala J
    Biochem J; 1992 Oct; 287 ( Pt 2)(Pt 2):657-61. PubMed ID: 1445226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of calpain by peptidyl fluoromethyl ketones.
    Angliker H; Anagli J; Shaw E
    J Med Chem; 1992 Jan; 35(2):216-20. PubMed ID: 1732539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological activity of a series of potent fluoromethyl ketone inhibitors of recombinant human calpain I.
    Chatterjee S; Ator MA; Bozyczko-Coyne D; Josef K; Wells G; Tripathy R; Iqbal M; Bihovsky R; Senadhi SE; Mallya S; O'Kane TM; McKenna BA; Siman R; Mallamo JP
    J Med Chem; 1997 Nov; 40(23):3820-8. PubMed ID: 9371247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of benzyloxycarbonyl[125I]iodotyrosylalanyldiazomethane as a probe for active cysteine proteinases in human tissues.
    Mason RW; Bartholomew LT; Hardwick BS
    Biochem J; 1989 Nov; 263(3):945-9. PubMed ID: 2597135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The major calpain isozymes are long-lived proteins. Design of an antisense strategy for calpain depletion in cultured cells.
    Zhang W; Lane RD; Mellgren RL
    J Biol Chem; 1996 Aug; 271(31):18825-30. PubMed ID: 8702541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of cysteine proteinase activity by Z-Phe-Phe-diazomethane and of aspartic proteinase activity by pepstatin in different organs from some animals and isolated cells from rat liver.
    Riemann S; Kirschke H; Wiederanders B; Brouwer A; Shaw E; Bohley P
    Acta Biol Med Ger; 1982; 41(1):83-8. PubMed ID: 7051705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Collagenolytic cysteine proteinases of bone tissue. Cathepsin B, (pro)cathepsin L and a cathepsin L-like 70 kDa proteinase.
    Delaissé JM; Ledent P; Vaes G
    Biochem J; 1991 Oct; 279 ( Pt 1)(Pt 1):167-74. PubMed ID: 1930136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of proteolytic variables in a lean and obese strain of pig at the ages of 2.5 and 7 months.
    Kretchmar DH; Koohmaraie M; Mersmann HJ
    Lab Anim Sci; 1994 Feb; 44(1):38-41. PubMed ID: 7516455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A selective cysteine protease inhibitor is non-toxic and cerebroprotective in rats undergoing transient middle cerebral artery ischemia.
    Seyfried DM; Veyna R; Han Y; Li K; Tang N; Betts RL; Weinsheimer S; Chopp M; Anagli J
    Brain Res; 2001 May; 901(1-2):94-101. PubMed ID: 11368955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.